3-K

(Exact name of registrant as specified in its charter)

DELAWARE 001-35068 41-2193603 (State of incorporation) (Commission File No.) (IRS Employer Identification No.)

351 Galveston Drive


Redwood City, CA 94063

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (650) 216-3500

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Item 2.02 Results of Operations and Financial Condition

On March 7, 2019, AcelRx Pharmaceuticals, Inc. (the "*Company*"), issued a press release entitled "AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results" regarding its financial results for the fourth quarter and year ended December 31, 2018, a business update and certain other information. The full text of the press release concerning the foregoing is furnished herewith as Exhibit 99.1.

The information contained in this Item 2.02 shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 to this Current Report shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the "SEC") under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01	Financial Statements and Exhibits

(d) Exhibits.

Exhibit

Description

Number

99.1 Press Release dated March 7, 2019 entitled "AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results"

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 7, 2019 ACELRX PHARMACEUTICALS, INC.

/s/ Raffi By: Asadorian

Raffi Asadorian

Chief Financial Officer